Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (Q36712981)

15 August 2017

1 reference

title

Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (English)

1 reference

secondary hyperparathyroidism

15 August 2017

0 references

1 reference

1 reference

2

Eduardo Slatopolsky

1 reference

15 August 2017

Alex J Brown

1

1 reference

PubMed ID

17237840

15 August 2017

language of work or name

1 reference

1 February 2007

1 reference

Nature Clinical Practice Endocrinology and Metabolism

15 August 2017

1 reference

15 August 2017

3

1 reference

15 August 2017

2

1 reference

15 August 2017

134-144

1 reference

Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Studies on the mechanism of action of calciferol VII. Localization of 1,25-dihydroxy-vitamin D3 in chick parathyroid glands

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

1,25(OH)2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Synthetic studies of vitamin D3 analogues. VIII. Synthesis of 22-oxavitamin D3 analogues

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Effects of calcitriol, 22-oxacalcitriol, and calcipotriol on serum calcium and parathyroid hormone gene expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1 alpha,25-dihydroxyvitamin D3

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

On the mechanisms for the selective action of vitamin D analogs

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

The binding properties, with blood proteins, and tissue distribution of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a noncalcemic analogue of 1 alpha, 25-dihydroxyvitamin D3, in rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Disposition and metabolism of F6-1alpha,25(OH)2 vitamin D3 and 1alpha,25(OH)2 vitamin D3 in the parathyroid glands of rats dosed with tritium-labeled compounds

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Clinical Trial of 26,26,26,27,27,27-Hexafluoro-1,25-Dihydroxyvitamin D3 in Uremic Patients on Hemodialysis: Preliminary Report

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Renal osteodystrophy in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Effects of long-term therapy with calcitriol in patients with moderate renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol(2).

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

New developments in hyperphosphatemia management

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors--new prospects for treatment of hyperparathyroidism with vitamin d.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0394

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0394

1 reference

15 August 2017

1 reference

PubMed ID

17237840